Management of hypertension and its sequelae with ACE inhibitors: Biochemical, pharmacological and clinical aspects

International Journal of Clinical Practice

Volumn 52, Issue 7, 1998, Pages 492-500

  Rangoonwala, B ^a,b   Rosenthal, J ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CLINICAL FEATURE; DIABETIC NEPHROPATHY; DRUG MECHANISM; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HYPERTENSION; PRIORITY JOURNAL; REVIEW;

EID: 0031761684     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Sixth Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
2. Hansson L, Dahlof B, Himmelmann A, Svensson A. Angiotensin-converting enzyme inhibitors in the treatment of essential hypertension. In: Robertson JIS, Nicholls MG, Eds. The Renin-Angiotensin System. London: Gower Medical Publishing 1993; 91: 1-91.
3. Crozier IG, Ikram H, Nicholls MG. Angiotensin-converting enzyme inhibitors in the treatment of heart failure. In: Robertson JIS, Nicholls MG, Eds. The Renin Angiotensin System. London: Gower Medical Publishing 1993; 94: 1-94.
4. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
5. Kasiske BL, Kalil RSN, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-138.
6. Pitt B, Segal R, Martinez FA et al, on behalf of Elite Study Investigators. Randomised trial of losartan versus captopril in patients with heart failure: Evaluation of Losartan in the Elderly Study (ELITE). Lancet 1997; 349: 747-752.
7. Bender N, Rangoonwala B, Rosenthal J, Vasmant D. Physicochemical and enzyme binding kinetic properties of a new angiotension-converting enzyme inhibitor ramipril and their clinical implications. Clin Physiol Biochem 1990; 8 (suppl 1): 44-52.
8. Ranadive SA, Chen AX, Serajuddin ATM. Relative lipophilicities and structural pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm Res 1992; 9: 1480-1486.
9. Dzau VJ. Tissue angiotensin systems in cardiovascular disease. In: Braunwald E, Ed. Heart disease update. London: WB Saunders 1994; 485-493.
10. Unger Th, Gohike P. Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. Cardiovasc Res 1994; 28: 146-158.
11. Buenning P. Kinetic properties of the angiotensin-converting enzyme inhibitor ramiprilat. J Cardiovasc Pharmacol 1987; 10(suppl 7): S31-S35.
12. Moursi M. Ganten D, Lang RE, Unger Th. Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril and perindopril in stroke-prone spontaneously hypertensive rats. J Hypertens 1986; 4(suppl 3): S495-S498.
13. Unger Th, Fleck T, Ganten D et al. 2-N-(S)-1-ethoxycarbonyl-3 phenylpropyl-L-alanyl-(1S,35,5S)-2-azabicyclol-[3,3,0]-octane 3 carboxylic acid (Hoe498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats. Drug Res 1984; 34: 426-430.
14. Erman A, Winkler J, Chen-Gal B et al. Inhibition angiotensin converting enzyme by ramipril in serum and tissue of man. J Hypertens 1991; 9: 1057-1062.
15. Johnston D, Duffin D. Drug-patient interactions and their relevance in the treatment of heart failure. Am J Cordiol 1992; 69: 8C-16C.
16. Frampton JE, Peters DH. Ramipril: an updated review of its therapeutic use in essential hypertension and heart failure. Drugs 1995; 49(3): 440-466.
17. Vertes V, Haynie R. Comparative pharmacokinetics of captopril, enalapril, and quinapril. Am J Cardiol 1992; 69: 8C-16C.
18. Johnston CI, Fabris B, Yamada H et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989; 7(suppl 5): 511-516.
19. Lancaster SG, Todd PA. Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-669.
20. Verho M, Luck C, Stelter WJ et al. Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. Curr Med Res Opin 1995; 13: 264-273.
21. Balfour JA, Goa KL. Benazepril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 1991; 42(3): 511-539.
22. Wiseman LR, McTavish D. Trandolapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994; 48(1): 71-90.
23. Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1986; 31: 198-248.
24. Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet 1993; 24(3): 230-254.
25. Scholkens BA, Linz W, Konig W. Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischaemic rat heart are abolished by a bradykinin antagonist. J Hypertens 1988; 6(suppl 4): 525-528.
26. Linz W, Wiemer G, Schölkens BA. ACE inhibition induces NO formation in cultured bovine endothelial cells and protects isolated ischaemic rat hearts. J Mol Cell Cardiol 1992; 24: 909-919.
27. Schölkens BA, Linz W, Martorana PA. Experimental cardiovascular benefits of angiotensin converting enzyme benefits of angiotensin converting enzyme inhibitors: beyond blood pressure reduction. J Cardiovasc Pharmacol 1991; 18(suppl 2): S26-S30.
28. Cooke JP, Singer AH, Tsao P et al. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90: 1168-1172.
29. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci 1990; 87: 5193.
30. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leucocyte adhesion. Proc Natl Acad Sci 1991; 88: 4651.
31. Becker RHA, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991; 18(suppl 2): S110-S115.
32. Chen X, Hu YC, Scholkens BA, Lee TJF. Ramipril reverses oxidised LDL-induced inhibition of vasodilation and attenuates atherosclerosis in cholesterol-fed rabbits (abstract). Fed Am Soc Exper Biol J 1994; 8(Pt II): abstract 3842.
33. Yamamoto S, Takemori E, Hasegawa Y et al. General pharmacology of the novel angiotensin converting enzyme inhibitor benazapril hydrochloride. Arzneim Forsch/Drug Res 1991; 41(II): 913-923.
34. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the watanabe heritable hyperlipidemic rabbit. Hypertension 1992; 20: 473-477.
35. Wiemer G, Scholkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991; 18: 558-563.
36. Busse R, Fleming I, Hecker M. Endothelium-derived bradykinin: implications for angiotensin converting enzyme inhibitor therapy. J Cardiovasc Pharmacol 1993; 22(suppl 5): S31-S36.
37. Graefe M. Bossaller C, Graf K et al. Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells. Am J Physiol 1993: 264: H1493-1497.
38. Wiemer G. Schölkens BA, Becker RHA. Converting enzyme inhibitor-stimulated formation of nitric oxide and prostacyclin in endothelial cells from bovine aorta is mediated by endothelium-derived bradykinin. In: Bönner G, Fritz H, Schölkens BA et al, Eds. Recent Progress on Kinins. Agents and Actions Supplements. Basel: Birkhäuser Verlag 1992; 38/III: 196-200.
39. Auch-Schwelk W, Kuchenbuch M, Claus B et al. Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors. Eur Heart J 1993; 14(suppl I): 154-160.
40. Edwards CRW, Padfield PI. Angiotensin converting enzyme inhibitors: past, present and bright future. Lancet 1985; i: 30-34.
41. Williams GM. Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988; 319: 1517-1525.
42. Brandt D. Therapie der arteriellen Hypertonie mit dem ACE-Hemmer Ramipril: Ergebnisse der Osterreichischen multicenter-ramipril-Studie (ART1). Therapie Osterreich 1992; 7: 394-400.
43. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1513.
44. Agabiti-Rosei E, Ambrosioni E, Dal Palu C et al. ACE inhibitor ramipril is more effective than the ß-blocker atenolol in reducing left ventricular mass in hypertension: results of the RACE (ramipril cardioprotective evaluation) study. J Hypertens 1995; 13: 1325-1334.
45. Bjorck S, Mulec H. Johnsen SA et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-343.
46. Weidmann P, Boehlen LM, De Courten M. Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 1993; 8: 582-584.
47. Croog SH, Levine S, Testa MA et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657-1664.
48. Fletcher AE, Bulpitt CJ. The measurement of quality of life in evaluating ACE inhibitors. J Hum Hypertens 1990; 4(suppl 4): 45-50.
49. Kundu SC, Bhattacharya A, Vakil HB. Ramipril and α-methyldopa compared in patients with mild to moderate hypertension. Clin Ther 1990; 12: 393-397.
50. Weidmann P, Ferrari P. Die antihypertensive Therapie in den neunziger Jahren. Praxis 1992; 81: 188-198.
51. Leonetti G, Cuspidi C. Choosing the right ACE inhibitor: a guide to selection. Drugs 1995; 49(4): 516-535.
52. Nami R, Pavese G, Panza F et al. Comparative evaluation of the antihypertensive effect and the tolerability of different ACE inhibitors in the medium term treatment of essential hypertension (in Italian). G Ital Ric Clin Ter 1992; 13: 107-116.
53. Yasky J, Verho M, Erasmus TP et al. Efficacy of ramipril versus enalapril in patients with mild to moderate essential hypertension. Br J Clin Pract 1996; 50(6): 302-310.
54. Lueders S, Schrader J, Schoel G et al. 24-hour blood pressure measurement for evaluation of first-dose response of captopril and ramipril in patients with stimulated renin system (in German). Z Kardiol 1992; 81(suppl 2):41-44.
55. Lacouciera Y, Poirer L, Provencher P, Guivarch PH. Once vs twice daily administration of a fixed combination of captopril plus hydrocholorothiazide in essential hypertension: a double-blind crossover study in known responders to a standard combination. Br J Clin Pharmacol 1991; 32: 115-119.
56. Heidbreder D, Froer K-L, Breitstadt A et al. Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension: Part 1-A, double-blind comparative multicenter study in nonresponders to ramipril monotherapy. Clin Cardiol 1992; 15: 904-910.
57. Letellier P, Overlack A, Agnes E, Desche P. Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double blind multicentre study. J Hum Hypertens 1994; 8: 145-149.
58. Luscher TF, Waeber B. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension. J Cardiovasc Pharmacol 1993; 21: 305-309.
59. Materson BJ, Reda DJ, Cushman WC et al, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-921.
60. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide captopril, and to combination in black and white mild to moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7: 52-55.
61. Zabludowski J, Rosenfeld J, Akbary MA et al. A multi-centre comparative study between ramipril and enalapril in patients with mild to moderate essential hypertension. Curr Med Res Opin 1988; 11: 93-106.
62. Rudy MC, Mroczek WJ. Comparison of ramipril and enalapril in patients with essential hypertension. Pharmacotherapy 1993; 13: 224-228
63. Zannad F, Matzinger A, Larche J. Trough/peak ratio of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996; 9: 633-643.